The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frey, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frey, A. B.

The Journal of Immunology, Vol 154, Issue 9 4613-4622, Copyright © 1995 by American Association of Immunologists


ARTICLES

Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo

AB Frey
Department of Cell Biology, New York University School of Medicine, NY 10016, USA.

Rat adenocarcinoma 13762 was modified by transfection to express IFN- gamma, and the tumor-forming potential of cytokine-producing cells was found to be dramatically impaired. Animals resistant to inocula of IFN- gamma-modified tumor were resistant to subsequent challenge with unmodified 13762 tumor. Induced immunity was tumor specific in that syngeneic but non-cross-reactive tumor grew with normal kinetics in animals injected with IFN-gamma-producing 13762 tumor. Antitumor T cells were derived from animals primed with IFN-gamma-producing 13762 tumor and expanded into a cell line by coculture in vitro with IFN- gamma-producing 13762 cells. Anti-13762-gamma T cells were cytotoxic in vitro toward IFN-gamma-producing 13762 tumor and were not reactive with other syngeneic tumors or spleen B cells. Anti-13762-gamma T cells were determined to be CD4+ by Ab staining and flow cytometric analysis, and recognition of 13762-gamma in vitro was inhibited by anti-MHC class II Ab. Anti-13762-gamma T cells were not reactive in vitro with wild-type 13762 tumor unless treated with exogenous rIFN-gamma, which induced expression of cell surface MHC class II. However, adoptively transferred anti-13762-gamma T cells could effect regression of wild- type 13762 tumor or dramatically inhibit progressive growth in animals carrying significant tumor burden, and the antitumor phenotype did not require CD8+ T cells in vivo. These experiments demonstrate that although antitumor T cells elicited against cytokine-modified tumor may fail to demonstrate reactivity with unmodified tumor in vitro, antitumor properties may be manifest in vivo.


This article has been cited by other articles:


Home page
Cancer Res.Home page
C.-W. Liao, C.-A. Chen, C.-N. Lee, Y.-N. Su, M.-C. Chang, M.-H. Syu, C.-Y. Hsieh, and W.-F. Cheng
Fusion Protein Vaccine by Domains of Bacterial Exotoxin Linked with a Tumor Antigen Generates Potent Immunologic Responses and Antitumor Effects
Cancer Res., October 1, 2005; 65(19): 9089 - 9098.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. D. Hess, N. K. Egilmez, N. Bailey, T. M. Anderson, E. Mathiowitz, S. H. Bernstein, and R. B. Bankert
Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-{gamma}
J. Immunol., January 1, 2003; 170(1): 400 - 412.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. K. Egilmez, S. D. Hess, F.-A. Chen, H. Takita, T. F. Conway, and R. B. Bankert
Human CD4+ Effector T Cells Mediate Indirect Interleukin-12- and Interferon-{gamma}-dependent Suppression of Autologous HLA-negative Lung Tumor Xenografts in Severe Combined Immunodeficient Mice
Cancer Res., May 1, 2002; 62(9): 2611 - 2617.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Huang, F. Li, J. R. Gordon, and J. Xiang
Synergistic Enhancement of Antitumor Immunity with Adoptively Transferred Tumor-specific CD4+ and CD8+ T Cells and Intratumoral Lymphotactin Transgene Expression
Cancer Res., April 1, 2002; 62(7): 2043 - 2051.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
O. Utermohlen, C. Schulze-Garg, G. Warnecke, R. Gugel, J. Lohler, and W. Deppert
Simian Virus 40 Large-T-Antigen-Specific Rejection of mKSA Tumor Cells in BALB/c Mice Is Critically Dependent on both Strictly Tumor-Associated, Tumor-Specific CD8+ Cytotoxic T Lymphocytes and CD4+ T Helper Cells
J. Virol., November 15, 2001; 75(22): 10593 - 10602.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. D. Weinberg, M.-M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
J. Immunol., February 15, 2000; 164(4): 2160 - 2169.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Mumberg, P. A. Monach, S. Wanderling, M. Philip, A. Y. Toledano, R. D. Schreiber, and H. Schreiber
CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma
PNAS, July 20, 1999; 96(15): 8633 - 8638.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Kayagaki, N. Yamaguchi, M. Nakayama, A. Kawasaki, H. Akiba, K. Okumura, and H. Yagita
Involvement of TNF-Related Apoptosis-Inducing Ligand in Human CD4+ T Cell-Mediated Cytotoxicity
J. Immunol., March 1, 1999; 162(5): 2639 - 2647.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.